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ABSTRACT
Introduction: We evaluate the association
between caregiver (informal) time/cost and
illness severity from two recently completed
clinical trials of an investigational drug for
Alzheimer’s disease (AD).
Methods: Changes from baseline caregiver time
were calculated and treatment effects analyzed
using a restricted maximum likelihood-based
mixed model for repeated measures. Four
separate models were then estimated to
examine the association between caregiver
time costs and the clinical endpoints measured
during the trials, including cognition (MMSE),
function (DAD), behavior (NPI), global
disability (CDR) and dependence (DS).
Results: Caregiver time cost was significantly
associated with all clinical measures of illness
severity with a 1-unit change in MMSE, DAD,
NPI, CDR and DS associated with a 11.57%,
4.81–4.97%, 3.58–3.67%, 42.52% and 71.05%
change, respectively, in primary caregiver time
cost. The association between caregiver time
cost and DS was the strongest of all the
associations examined.
Conclusion: Caregiver time costs increase with
increasing AD severity in all key domains of AD
(cognition, function, behavior, global disability
and dependence on others). Our analysis
demonstrated that patient dependence is a
particularly important predictor of caregiver
time costs and should be considered as a
potential outcome measure in intervention
clinical trials in AD.
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Alzheimer’s disease is a progressive dementia
characterized by cognitive deficits, altered
behavior and inability to care for oneself. Sixty
to seventy percent of persons with AD live in
the community, with much of the care
provided by family or other unpaid persons
[1]. These unpaid caregivers provide an
estimated 17.4 billion hours of unpaid care per
year, constituting an estimated value of $210
billion [1]. The value placed on caregiver time,
informal care cost, represents the largest
component of the total cost of care for AD
[2–7]. Estimates range from 37% of total care
costs in community dwelling patients
participating in a study in Scandinavia [3] to
86% of the total cost of care in a clinical trial
sample of mild to moderate AD from multiple
countries [4]. A study of cost of illness in
dementia reported that 56% of total costs in
the EU27 in 2008 were contributed by informal
care costs [2]. In the US, Zhu et al. reported that
when patients with AD are not
institutionalized, informal care-giving cost
represents 70% of the total cost of care [7].
Given the important role of care-giving time
in the management of person with AD,
informal care time/cost has been included as
an outcome measure in evaluations of AD
treatments [8–12]. Some of these studies
reported significant reductions in caregiver
time with galantamine [8] and donepezil
treatment in patients with AD [8–11] and
others did not [12]. More recently, care-giving
time was included as an outcome measure in
two RCTs examining the efficacy of
bapineuzumab in mild to moderate AD, and is
the focus of this analysis [13].
In the economic evaluation of interventions
in AD, it is frequently necessary to model the
economic implications of changes in clinical
progression (e.g., MMSE), in order to determine
cost-effectiveness. Having robust estimates of the
associations between clinical progression
measures and economic outcomes, like
informal caregiver time, is very important for
such models. Many studies have reported a
significant association between informal
care-time (and -cost) and disease severity
measures of cognition [3–5], function [4, 5, 14]
and behavior [4, 5]. In Mauskopf et al.’s review of
the literature, they concluded that functional
and behavioral measures were consistently
associated with caregiver time [15]. Two recent
studies conducted comprehensive evaluations of
associations in AD [4, 5]. Gustavsson et al. [4]
examined the association between informal care
and measures of cognition (MMSE, ADAS-COG),
function (ADCS-AD), behavior (NPI-total and
NPI distress) and global disability (CDR-SOB)
using correlations. Whilst the authors provided
estimates of the proportional change in total care
cost with marginal change in clinical severity
measures, no estimates were provided
specifically for informal care cost. Rapp et al. [5]
provided estimates of the proportional changes
in informal care costs with marginal changes in
MMSE, ADL, NPI and ZBI but did not examine
associations with a global measure, like CDR-SOB
and the dependence scale (DS). The large dataset
from the two bapineuzumab randomized clinical
trials (RCTs) provide a rich dataset to investigate
associations between: (1) caregiver time and
baseline severity and (2) informal care costs and
baseline clinical severity measures, which are the
aims of this current study.
METHODS
Study Design
Data from two 18 month, multi-center,
randomized, double-blind, placebo
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controlled, parallel group trials examining
bapineuzumab in patients with mild to
moderate AD were merged in order to study
caregiver time patterns in AD. The two studies
had the same design: study ELN115727-301
(301) enrolled subjects with mild to moderate
Alzheimer’s disease (AD) who were
apolipoprotein E e4 (APOE*E4) non-carriers,
and they were randomly assigned to receive
bapineuzumab (0.5 and 1.0 mg/kg) or placebo
every 13 weeks for a total of six infusions.
Study ELN115727-302 (302) enrolled similar
subjects who were APOE*E4 carriers who were
randomized to receive either bapineuzumab
(0.5-mg/kg) or placebo by IV infusion. The
studies recruited subjects in sites in the US.
Informed consent was obtained from all
participants, or, if not capable of providing
informed consent, from their legally
acceptable representative. The studies were
conducted according to the Declaration of
Helsinki and were approved by the
Independent review board at each
participating site.
Subjects were enrolled in the study if they
were 50 to\89 years of age; had a diagnosis of
probable AD according to the National
Institute of Neurological and Communicative
Disorders and Stroke/Alzheimer’s Disease and
Related Disorders Association (NINCDS/
ADRDA) criteria and a screening visit brain
MRI scan consistent with a diagnosis of AD;
an MMSE score of 16–26 inclusive; a Rosen
Modified Hachinski Ischemic score B4 [16];
lived at home or independently in a
community dwelling and had a caregiver
who consented to participate in the study,
could accompany the subject on all clinic
visits, and was a reliable informant in the
opinion of the Investigator. Subjects were
excluded if they had clinically significant
neurological disease other than AD; a major
psychiatric disorder; history of stroke or
seizures; a brain MRI scan indicative of
significant non-AD abnormality; or history or
evidence of any clinically significant
autoimmune disease or chronic illness,
which was likely to result in deterioration
affecting the subject’s safety during the study.
The resource utilization of each patient was
assessed using the RUD-Lite [17], which was
administered at baseline, week 26, week 52,
and week 78. A brief summary of total costs
by cost category (direct medical, direct
nonmedical and informal costs) is presented
first. Since informal costs are the largest
category of costs, this paper provides
additional analysis on the caregiver time
component of the RUD-Lite. Caregiver time
was assessed for both primary and secondary
caregivers over the past month and was
calculated as the product of the average time
spent caring per day by the number of days in
a month spent caring. The primary caregiver
total time was calculated as the sum of
caregiver time allocated to instrumental
activities of daily living (IADL), activities of
daily living (ADL) and to supervision. The
secondary caregiver total time was calculated
in the same way. The total caregiver total time
is the sum of the primary caregiver time and
the secondary caregiver time, measured as
hours per month. For the purposes of
assigning costs, the number of caregiver
hours was capped at 16 h per day to allow
for 8 h of sleep per night, which is consistent
with the approach taken by other researchers
[18]. Caregiver time was costed by assigning
30% of the average hourly wage of $23.54
($7.06) to account for lost leisure time and
not full hourly wage. In the literature, others
have assigned 25–35% of the average hourly
wage to caregiver time to account for lost
leisure time [19–21].
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At each visit, cognitive function was assessed
using the Alzheimer’s Disease Assessment
Scale-Cognitive Subscale (ADAS-Cog; range
0–70) [22] and Mini Mental State Examination
(MMSE; 0–30) [23], functional ability with the
disability assessment for dementia (DAD; range
0–100%) [24] and neuropsychiatric symptoms
with the neuropsychiatric Inventory (NPI; range
0–144) [25]. Patient dependence on others was
assessed using the dependence scale (DS; range
0–15) [26]. Global disability was assessed using
the clinical dementia rating scale (CDR) [27]. In
addition, the age and gender of patients and
caregivers, their relationship, and marital status
was recorded.
Analysis
Total Cost Analysis Using Merged 301 and 302
Dataset
The resource use and estimated costs at each
visit corresponded to the 6-month period
preceding the visit (i.e. -26 to 0, 1–26, 27–52,
and 53–78 weeks). Unit costs ($US inflated to
2012) were applied to the resource use data
collected in the study. Table 1 provides details
of the component costs contributing to total
costs and the sources used.
Informal Caregiver Time Analysis Using
Merged 301 and 302 Dataset
The mean changes in primary caregiver and
secondary caregiver time at week 78 were
determined for three sub-groups of patients
with the following baseline severity: (1) very
mild (MMSE C 24); (2) mild (MMSE C 21); (3)
moderate (MMSE\21).
To understand the relative distribution of
time across different caring tasks, the mean
times primary caregivers allocated to IADLs,
ADLs and supervision at baseline and week 78
were estimated using the merged dataset.
Informal Care Cost Analysis Using Merged 301
and 302 Dataset
Using generalized linear modelling (GLM), the
association between caregiver time cost over the
previous 6 months and baseline clinical
measures of severity was estimated. Caregiver
time costs were log transformed to improve
normality. Four models were investigated: the
first examined associations with cognition
(MMSE), function (DAD) and behavior (NPI);
the second with an alternative measure of
cognition (ADAS-COG), as well as function
(DAD) and behavior (NPI); the third with a
global measure (CDR-SOB) and the fourth with
an alternative global measure (DS). All models
controlled for patient age and gender.
RESULTS
Caregiver and Patient Demography
and Characteristics
Baseline patient demographics are presented in
Table 2 and caregiver demographics in Table 3.
A total of 2204 patients participated in the 301
and 302 studies and were randomized to receive
either placebo (925) or bapineuzumab (1279).
The two groups in each study were similar at
baseline with respect to patient age, gender,
duration of AD and severity of AD, as measured
by the MMSE. The mean for the total
population of 21.0 for MMSE is consistent
with the Mild to Moderate AD entry criteria.
The two groups in each study were similar with
respect to caregiver characteristics.
Approximately 90%, overall, lived with the
patient (Table 3). Approximately 75% of
primary caregivers reported that there were no
other caregivers (Table 3).
In comparison with other recent survey
data on caregivers of Alzheimer’s patients
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[1], caregivers in the 301 and 302 studies
tended to be older on average (65 versus
52 years of age), less likely to be female (60%
versus 70% female), and more likely to be
the spouse of the subject (70% versus
6–17%).
Table 1 $US unit costs assigned to resource use components of Rud-lite
Accommodation
Intermediate forms of accommodation (not dementia-speciﬁc) (per day)a $116.71
Dementia-speciﬁc residential accommodation (per day)a $158.04
Long-term institutional care/nursing home -private room (per day)a $261.00
Community services
Registered nurse home visits (per visit)b,h $139.08
Home health aide/orderly (per hour)a $21.00
Food delivery/Meals on wheels (per meal)c $8.00
Day care (per day)a $70.00
Transportation (publicly/insurance paid) (round trip)a $20.00
Inpatient care
Geriatric (per night)d,h $7220.37
Psychiatric (per night)d,h $7220.37
Internal Medicine (per night)d,h $7220.37
Surgery (per night)d,h $7220.37
Other (per night)d,h $7220.37
ER (per visit)e,h $1401.20
Outpatient care
General practitioner (per visit)f,h $148.13
Geriatrician (per visit)f,h $148.13
Neurologist (per visit)f,h $148.13
Psychiatrist (per visit)f,h $148.13
Physiotherapist (per visit)f,h $148.13
Occupational therapist (per visit)f,h $148.13
Social worker (per visit)f,h $148.13
Psychologist (per visit)f,h $148.13
Other (specialist, please specify) (per visit)f,h $148.13
Caregiving time
Caregiver informal care time (per hour)g $7.06
a Metlife Mature Market Institute—Market Survey of Long-Term Care Costs (Nov 2012)
b CPT code 99349, page 83 of 2008 PF&CG (inﬂated to 2012 dollars)
c http://www.sdslane.org/mow.html
d HCUP All cause hospitalization discharges, 2010 (inﬂated to 2012 dollars)
e HCUP Emergency Department State Statistics, 2005 (inﬂated to 2012 dollars)
f CPT code 99243, page 69 of 2008 PF&CG (inﬂated to 2012 dollars)
g Employment, hours, and earnings from the current employment statistics survey (National)
h Medical care inﬂation index
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Total Cost Analysis Using Merged 301
and 302 Dataset
Based on the merged dataset, the mean total
and component costs of care are presented for
each visit in Fig. 1. The mean total cost of care
for the previous 6 months was estimated to be
US $9144 at baseline and US$ 17,066 at week
78. The total cost of care includes informal care
costs (based on caregiver time) and the cost of
healthcare (direct medical cost) and social care
services used (direct nonmedical costs). Direct
Table 2 Patient demographics and baseline characteristics














N 493 621 432 658 2204
Mean (SD) 71.9 (10.10) 73.1 (9.35) 72.3 (8.40) 72.0 (8.03) 72.4 (8.94)
Gender, n (%)
Male 245 (49.7) 281 (45.2) 190 (44.0) 300 (45.6) 1016 (46.1)
Female 248 (50.3) 340 (54.8) 242 (56.0) 358 (54.4) 1188 (53.9)
Duration of AD (years)
N 493 621 432 658 2204
Mean (SD) 3.1 (2.32) 3.1 (2.43) 3.5 (2.48) 3.4 (2.37) 3.2 (2.40)
MMSE
N 493 621 452 658 2204
Mean (SD) 21.2 (3.21) 21.2 (3.31) 20.7 (3.17) 20.8 (3.15) 21.0 (3.22)
ADAS-COG
N 493 621 432 658 2204
Mean (SD) 22.2 (10.08) 22.3 (9.85) 23.9 (9.52) 23.5 (9.44) 22.9 (9.74)
DAD
N 493 621 432 658 2204
Mean (SD) 80.5 (19.5) 80.2 (18.46) 79.4 (18.85) 80.9 (17.32) 80.3 (18.36)
NPI
N 479 603 423 642 2147
Mean (SD) 11.2 (12.42) 11.0 (12.60) 10.1 (11.75) 10.0 (11.85) 10.6 (12.18)
DS
N 493 619 431 658
Mean (SD) 4.6 (2.23) 4.6 (2.29) 4.8 (2.0) 4.7 (2.07) 4.7 (2.16)
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N 491 617 429 655
Mean (SD) 64.9 (13.28) 64.0 (13.75) 65.4 (12.30) 65.5 (12.07)
Gender, n (%)
Male 181 (36.7) 243 (39.2) 185 (42.9) 281 (42.8)
Female 312 (63.3) 377 (60.8) 246 (57.1) 375 (57.2)
Missing 0 1 1 2
Relationship to subject, n (%)
Husband 141 (28.6) 182 (29.4) 152 (35.3) 236 (36.0)
Wife 213 (43.2) 229 (36.9) 170 (39.4) 261 (39.8)
Child 94 (19.1) 143 (23.1) 74 (17.2) 114 (17.4)
Friend 13 (2.6) 19 (3.1) 10 (2.3) 19 (2.9)
Healthcare professional 3 (0.6) 7 (1.1) 6 (1.4) 3 (0.5)
Other 29 (5.9) 40 (6.5) 19 (4.4) 22 (3.4)
Missing 0 1 1 3
Marital status, n (%)
Married/cohabitating 430 (87.6) 533 (86.5) 380 (89.2) 588 (89.8)
Never married 25 (5.1) 37 (6.0) 12 (2.8) 27 (4.1)
Divorced/separated 27 (5.5) 28 (4.5) 29 (6.8) 29 (4.4)
Widowed 9 (1.8) 18 (2.9) 5 (1.2) 11 (1.7)
Missing 2 5 6 3
Do you live with the subject? n (%)
Yes 406 (88.8) 235 (82.7) 359 (93.5) 544 (94.9)
No 51 (11.2) 49 (17.3) 25 (6.5) 29 (5.1)
Missing 36 23 48 85
How many additional caregivers? n (%)
0 367 (74.9) 442 (71.4) 325 (75.6) 476 (72.7)
1 73 (14.9) 111 (17.9) 56 (13.0) 101 (15.4)
2 28 (5.7) 38 (6.1) 27 (6.3) 38 (5.4)
3 10 (2.0) 14 (2.3) 10 (2.3) 23 (3.5)
C4 12 (2.4) 14 (2.3) 12 (2.8) 17 (2.6)
Missing 3 2 2 3
a Bapineuzumab 0.5 and 1.0 mg/kg pooled
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medical costs increased 45% over the 78 week
period, from $2591 at baseline to $3746 at week
78. Direct nonmedical costs increased 54%,
from $1323 at baseline to $2038 at week 78.
Caregiver time increased 116%, from $5230 at
baseline to $11,282 at week 78. Caregiver time
represented the largest percentage of total care
costs, at 57.2% at baseline and 66.1% at week
78. Other than caregiver time, the only
component of total care costs to increase its
percentage contribution to total care cost from
baseline (4.5%) to week 78 (7.1%) was
community care cost.
Informal Caregiver Time Analysis Using
Merged 301 and 302 Dataset
The mean primary caregiver time and secondary
caregiver time at baseline and week 78 are
presented for three sub-groups of patients
defined by their baseline MMSE into very
mild, mild and moderate AD and for the total
sample in Fig. 2. In general, both the baseline
and week 78 mean caregiver time tended to
increase with increasing severity of the
sub-groups. In addition, the mean change in
caregiver time at week 78 tended to increase
with increasing severity.
The mean primary caregiver time over each
time point is presented in Fig. 3. Primary
caregiver time increased by approximately
15–20 h every 6 months.
The mean primary caregiver time allocated
to IADLs, ADLs and supervision at baseline and
week 78 is presented in Fig. 4. At baseline and
week 78, primary caregiver time allocated to
IADLs tended to be greater than time allocated
to supervision, which tended to be greater than
the time allocated to ADLs. An examination of
Fig. 1 Mean costs for previous 6 months from baseline to
week 78
Fig. 2 Mean caregiver time (hours per month) by baseline
severity, as measured by the MMSE
Fig. 3 Mean primary caregiver time (hours per month)
over time using pooled dataset
Neurol Ther
changes at week 78 suggests that total primary
caregiver time increased considerably,
particularly for supervision and ADLs.
Associations Between Caregiver Time
Costs and Clinical Severity
The results of model estimates are presented in
Table 4. The beta coefficient estimates the
proportional change in the cost outcome for a
unit change in the explanatory variable (e.g.,
MMSE). That is, for a 1-unit increase in the
explanatory variable, cost increases by 100%
beta. The models demonstrated significant
associations between both log primary
caregiver time and log total caregiver time cost
over 6 months and clinical severity measures.
Based on the beta coefficients for model 1, a
1-unit change in MMSE is associated with an
11.57% change in primary caregiver time cost
and a 12.06% change in total caregiver time
costs. Based on models 1 and 2, a 1-unit change
in DAD is associated with a 4.81–4.97% change
in primary caregiver time cost and 4.98–5.25%
change in total caregiver time cost. Similarly, a
1 unit change in NPI is associated with a
3.58–3.67% increase in primary caregiver time
cost and 3.85–3.97% increase in total caregiver
time cost. Model 3 suggests that a 1-unit change
in CDR-SOB is associated with a 42.52%
increase in primary caregiver time cost and
45.16% increase in total caregiver time cost. The
higher R2 for Model 4 suggests that association
between DS and caregiver time cost is the
strongest of all of the associations tested in
Models 1–4. A 1-unit change in DS was
associated with a 71.05% change in primary
caregiver time cost and 73.67% increase in total
caregiver time cost.
Patient age and gender were not significantly
associated with either primary caregiver time
costs or total caregiver time costs.
DISCUSSION
The lack of significant treatment differences in
change in caregiver time at week 78 in the 301
and 302 study is consistent with the previously
reported lack of clinical efficacy of
bapineuzumab [17]. However, the large sample
size (2000? patients), longitudinal data
(18 months), and data on a wide spectrum of
clinical measures provided an opportunity to
thoroughly investigate how caregiver time
changes with patient severity and to quantify
Fig. 4 Mean primary
caregiver time (hours
per month) allocated
to different tasks at
baseline, week 78 and




























































































































































































































































































































































































































































































































































































































































































associations with a comprehensive set of
clinical severity measures.
The trend towards increasing caregiver time
with increasing cognitive decline, as measured
by the MMSE, observed in our cross-sectional
analysis, was consistent with previous reports
[4]. The trend towards greater changes in
caregiver time for the more severe sub-groups,
was a new observation but still consistent with
the above trend. The larger proportion of
care-giving time dedicated to IADLs than
supervision and ADLs at baseline in our
sample is consistent with the functional and
behavioral deficits experienced by patients with
mild to moderate AD. Interestingly, the greatest
changes over the 78 week period were related to
supervision. Typically, in AD, supervision is
required to prevent wandering, falls, and other
accidents.
The significant associations between clinical
severity measures and informal care time are
consistent with other reports [3–5, 15, 16]. The
proportional change in primary caregiver (11%)
and total caregiver time cost (12%) with a unit
change in MMSE is higher than the 4.7 estimate
reported by Rapp et al. [5]. The authors are
unaware of any previous publications
presenting the proportional change in
informal care cost with unit change in DAD; it
is not possible to compare our estimate of
4.97–5.15% change in informal care cost with
marginal change in DAD. A comparison of
R-squared for Models 1–4, suggests that the DS
was the best predictor of informal care costs
with the beta coefficient suggesting a 71–73%
change in informal care cost with a one unit
change in DS. Earlier studies have estimated
that the DS worsens by 1 point per year [28].
The levels of change were much higher than
that reported by Zhu et al. in their analysis of
Predictor study dataset [29]. They reported that
a one point increase in DS was associated with a
$1690 increase in informal cost. As the baseline
mean informal cost was $12,808 in their study,
the proportional change is considerably lower
than our analysis showed. Our model differs
from the Zhu model in that we did not include a
functional measure as an additional
explanatory variable in Model 4. Preliminary
analysis suggested a strong correlation
(r = -0.630) between the DS and DAD, so we
were concerned about multicollinearity effects.
There are a number of limitations associated
with our analysis. Firstly, the sample is a clinical
trial population, who must meet stringent
inclusion and exclusion criteria, and so may not
be representative of the general AD population.
Secondly, the RUD-Lite utilizes self-reported
data by caregivers. Hence, the resource use data
collection relies on accurate and consistent
recall from caregivers estimating the health
care resources used by the patient as well as
the time that they spent, on a daily basis, caring
for the patient. This element of the study may
be subject to an element of bias, both from
under- and over-estimations of resource use and
time spent in caregiving.
Thirdly, there is considerable debate about
how to assign costs to caregiver time. The
approach taken can influence greatly the
contribution of total cost of care attributed to
care giving time [3]. We assigned 30% of the
average hourly working rate.
Another limitation, highlighted by others [4]
is the possible overestimation of time per day.
For this reason we capped the daily care-giving
time at 16 h for the purposes of costing informal
care costs.
Whilst all of our four models were
significant, the levels of variation in informal
care cost explained ranged from 13% to 24% so
there was a considerable amount of variation
left unexplained. Other possible sources of
variation could be co-morbidities, or
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ethnic/cultural differences, but these were not
examined in this study.
CONCLUSION
Caregiver time costs increase with increasing
AD severity in all key domains of AD (cognition,
function, behavior, global disability, and
dependence on others). Our analysis
demonstrated that patient dependence is a
particularly important predictor of caregiver
time costs and should be considered as a
potential outcome measure in intervention
clinical trials in AD.
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